

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/485, 31/565, 9/00	A1	(11) International Publication Number: WO 98/31368 (43) International Publication Date: 23 July 1998 (23.07.98)
(21) International Application Number: PCT/GB98/00143 (22) International Filing Date: 16 January 1998 (16.01.98) (30) Priority Data: 9700878.3 17 January 1997 (17.01.97) GB (71) Applicant (for all designated States except US): R.P. SCHERER LIMITED [GB/GB]; Frankland Road, Blagrove, Swindon, Wiltshire SN5 8YS (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): JOHNSON, Edward, Stewart [GB/GB]; Willow Vale, Castle End Road, Ruscombe, Berkshire RG10 9XG (GB). CLARKE, Anthony [GB/GB]; 4 Pearces Meadow, Nettlebled, Henley-on-Thames, Oxfordshire RG9 5AF (GB). GREEN, Richard, David [GB/GB]; 4 Bridge Street, Monton, Marlborough, Wiltshire SN8 4HR (GB). (74) Agent: BOWMAN, Paul, Alan; Lloyd Wise, Tregear & Co., Commonwealth House, 1-19 New Oxford Street, London WC1A 1LW (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: DOSAGE FORMS AND METHOD FOR AMELIORATING MALE ERECTILE DYSFUNCTION (57) Abstract The use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, testosterone and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male erectile dysfunction.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DOSAGE FORMS AND METHOD FOR
AMELIORATING MALE ERECTILE DYSFUNCTION

This invention relates to dosage forms and methods for ameliorating erectile dysfunction in male patients. More particularly, this invention relates to the use of fast-dispersing dosage forms of drugs for amelioration of erectile dysfunction in male patients.

A normal erection occurs as a result of a coordinated vascular event in the penis. This is usually triggered neurally and consists of vasodilatation and smooth muscle relaxation in the penis and its supplying arterial vessels. Arterial inflow causes enlargement of the substance of the corpora cavernosa. Venous outflow is trapped by this enlargement, permitting sustained high blood pressures in the penis sufficient to cause rigidity. Muscles in the perineum also assist in creating and maintaining penile rigidity. Erection may be induced centrally in the nervous system by sexual thoughts or fantasy, and is usually reinforced locally by reflex mechanisms.

Male erectile dysfunction (MED) is defined as the inability to achieve and sustain an erection sufficient for intercourse. In any given case this can result from psychological disturbances (psychogenic), from physiological abnormalities in general (organic), from neurological disturbances (neurogenic), hormonal deficiencies (endocrine) or from a combination of the foregoing.

The effect of apomorphine on penile tumescence in male patients has been studied. These studies show that while apomorphine can indeed induce an erection in a psychogenic male patient, the apomorphine dose required to achieve a significant erectile response is usually accompanied by nausea or other serious undesirable side effects such as hypertension, flushing and diaphoresis. The specific mechanisms by which apomorphine acts to produce an erectile response in a human patient are not

yet completely understood, however.

Moreover, apomorphine has been shown to have very poor oral bioavailability. See, for example, Baldessarini et al., in Gessa et al., eds., Apomorphine and Other Dopaminomimetics, Basic Pharmacology, Vol. 1, Raven Press, N.Y. (1981), pp. 219-228.

WO95/28930 discloses sublingual apomorphine dosage forms, usually containing about 2.5 to about 10 milligrams of apomorphine, and dissolving in water within a time period of at least about 2 minutes but less than about 10 minutes, preferably about 3 minutes to about 5 minutes, have been found to be effective in male patients suffering from psychogenic erectile dysfunction for the induction and maintenance of an erection sufficient for intercourse (i.e. vaginal penetration) without nausea or other undesirable side effects. The apomorphine is administered sublingually, preferably about 15 to 20 minutes prior to sexual activity, and so as to maintain a predetermined circulating serum levels and mid-brain tissue levels of apomorphine during the period of sexual activity.

The foregoing sublingual apomorphine dosage forms are also suitable for screening patients complaining of erectile dysfunction so as to identify patients of psychogenic etiology.

PCT/GB96/02020 discloses a pharmaceutical composition for oral administration comprising a carrier and, as active ingredient, a dopamine agonist, in which the composition is in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity.

It was found that such fast-dispersing dosage forms promote pre-gastric absorption of the active ingredient, that is, absorption of the active ingredient from that part of the alimentary canal prior to the stomach. The term "pre-gastric absorption" thus includes buccal, sublingual, oropharyngeal and oesophageal absorption.

Dopamine agonists absorbed by such pre-gastric absorption pass straight into the systemic circulatory system thereby avoiding first pass metabolism in the liver.

Accordingly, bioavailability of dopamine agonists absorbed in this way may also be increased. This means that the dose of such dopamine agonists may be reduced whilst still producing the desired beneficial effects and this decrease in dose will result in a corresponding reduction of unwanted side effects.

10 The pharmaceutical compositions disclosed in PCT/GB96/02020 were developed for the treatment and/or evaluation of Parkinson's disease.

It has now been found that fast-dispersing dosage forms containing a dopamine agonist, such as apomorphine, may be used to treat male erectile dysfunction.

According to the present invention there is provided a pharmaceutical composition for oral administration for the treatment of male erectile dysfunction comprising a carrier and active ingredient comprising a dopamine agonist, testosterone or mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity.

The use of a fast-dispersing dosage form has several advantages over the use of conventional sublingual tablets.

The efficiency of the fast-dispersing dosage form allows low doses to be employed thereby reducing undesirable side effects, particularly nausea and vomiting.

The dosage form acts more quickly than sublingual tablets which allows the dose to be taken when it is required rather than a considerable time before sexual activity. This is both psychologically and socially preferable to sucking a tablet for several minutes in advance of sexual activity.

There is a faster offset of action since the active

ingredient is rapidly absorbed rather than absorbed over a prolonged period of time. The faster offset avoids painful persistent erection.

5 The rapid onset and offset of action is less likely to induce tolerance to the dopamine agonist.

One example of a fast-dispersing dosage form is described in U.S. Patent No. 4855326 in which a melt spinnable carrier agent, such as sugar, is combined with an active ingredient and the resulting mixture spun into
10 a "candy-floss" preparation. The spun "candy-floss" product is then compressed into a rapidly dispersing, highly porous solid dosage form.

U.S. Patent No. 5120549 discloses a fast-dispersing matrix system which is prepared by first solidifying a
15 matrix-forming system dispersed in a first solvent and subsequently contacting the solidified matrix with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, the matrix-
20 forming elements and active ingredient being substantially insoluble in the second solvent, whereby the first solvent is substantially removed resulting in a fast-dispersing matrix.

U.S. Patent No. 5079018 discloses a fast-dispersing
25 dosage form which comprises a porous skeletal structure of a water soluble, hydratable gel or foam forming material that has been hydrated with water, rigidified in the hydrated state with a rigidifying agent and dehydrated with a liquid organic solvent at a
30 temperature of about 0°C or below to leave spaces in place of hydration liquid.

Published International Application No. WO 93/12769 (PCT/JP93/01631) describes fast-dispersing dosage forms of very low density formed by gelling, with agar, aqueous
35 systems containing the matrix-forming elements and active ingredient, and then removing water by forced air or vacuum drying.

U.S. Patent No. 5298261 discloses fast-dispersing dosage forms which comprise a partially collapsed matrix network that has been vacuum-dried above the collapse temperature of the matrix. However, the matrix is preferably at least partially dried below the equilibrium freezing point of the matrix.

Published International Application No. WO 91/04757 (PCT/US90/05206) discloses fast-dispersing dosage forms which contain an effervescent disintegration agent designed to effervesce on contact with saliva to provide rapid disintegration of the dosage form and dispersion of the active ingredient in the oral cavity.

U.S. Patent No. 5,595,761 discloses a particulate support matrix for use in making a rapidly dissolving tablet, comprising:

a first polypeptide component having a net charge when in solution, e.g. non-hydrolysed gelatin;

a second polypeptide component having a net charge of the same sign as the net charge of the first polypeptide component when in solution e.g. hydrolysed gelatin; and

a bulking agent, and wherein the first polypeptide component and the second polypeptide component together comprise about 2% to 20% by weight of the particulate support matrix and wherein the bulking agent comprises about 60% to 96% by weight of the particulate support matrix; and

wherein the second polypeptide component has a solubility in aqueous solution greater than that of the first polypeptide component and wherein the mass : mass ratio of the first polypeptide component to the second polypeptide component is from about 1 : ½ to about 1 : 14; and

wherein when the support matrix is introduced into an aqueous environment the support matrix is disintegrable within less than about 20 seconds.

The term "fast-dispersing dosage form" therefore encompasses all the types of dosage form described in the preceding paragraphs. However, it is particularly preferred that the fast-dispersing dosage form is of the type described in U.K. Patent No. 1548022, that is, a solid fast-dispersing dosage form comprising a network of the active ingredient and a water-soluble or water-dispersible carrier which is inert towards the active ingredient, the network having been obtained by subliming solvent from a composition in the solid state, that composition comprising the active ingredient and a solution of the carrier in a solvent.

It is preferred that the composition of the invention disintegrates within 1 to 60 seconds, more preferably 1 to 30 seconds, especially 1 to 10 seconds and particularly 2 to 8 seconds, of being placed in the oral cavity.

In the case of the preferred type of fast-dispersing dosage form described above, the composition will preferably contain, in addition to the active ingredient, matrix forming agents and secondary components. Matrix forming agents suitable for use in the present invention include materials derived from animal or vegetable proteins, such as the gelatins, dextrans and soy, wheat and psyllium seed proteins; gums such as acacia, guar, agar, and xanthan; polysaccharides; alginates; carboxymethylcelluloses; carrageenans; dextrans; pectins; synthetic polymers such as polyvinylpyrrolidone; and polypeptide/protein or polysaccharide complexes such as gelatin-acacia complexes.

Other matrix forming agents suitable for use in the present invention include sugars such as mannitol, dextrose, lactose, galactose and trehalose; cyclic sugars such as cyclodextrin; inorganic salts such as sodium phosphate, sodium chloride and aluminium silicates; and amino acids having from 2 to 12 carbon atoms such as

glycine, L-alanine, L-aspartic acid, L-glutamic acid, L-hydroxyproline, L-isoleucine, L-leucine and L-phenylalanine.

One or more matrix forming agents may be
5 incorporated into the solution or suspension prior to solidification. The matrix forming agent may be present in addition to a surfactant or to the exclusion of a surfactant. In addition to forming the matrix, the
10 matrix forming agent may aid in maintaining the dispersion of any active ingredient within the solution or suspension. This is especially helpful in the case of active agents that are not sufficiently soluble in water and must, therefore, be suspended rather than dissolved.

Secondary components such as preservatives,
15 antioxidants, surfactants, viscosity enhancers, colouring agents, flavouring agents, pH modifiers, sweeteners or taste-masking agents may also be incorporated into the composition. Suitable colouring agents include red, black and yellow iron oxides and FD & C dyes such as FD &
20 C blue No. 2 and FD & C red No. 40 available from Ellis & Everard. Suitable flavouring agents include mint, raspberry, liquorice, orange, lemon, grapefruit, caramel, vanilla, cherry and grape flavours and combinations of these. Suitable pH modifiers include citric acid,
25 tartaric acid, phosphoric acid, hydrochloric acid and maleic acid. Suitable sweeteners include aspartame, acesulfame K and thaumatin. Suitable taste-masking agents include sodium bicarbonate, ion-exchange resins, cyclodextrin inclusion compounds, adsorbates or
30 microencapsulated actives.

It is preferred that the dopamine agonist is selected from 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol (apomorphine), 5,6,6a,7-tetrahydro-6-propyl-4H-dibenzo[de,g]quinoline-10,11-diol
35 (N-propylnorapomorphine), (5' α)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione (bromocriptine), 1-[(6-allyl)ergolin-8 β -yl]

carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
(cabergoline), N'-[(8 α)-9,10-didehydro-6-methylergolin-8-
yl]-N,N-diethylurea (lisuride), [[(8 β)-1,6-
dimethylergolin-8-yl]methyl]-carbamic acid phenylmethyl
5 ester (metergoline), (4aR)-trans-3,4,4a,5,6,10b-
hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-
ol (naxagolide), 8-[(methylthio)methyl]-6-
propylergoline (pergolide), 2-[4-(1,3-benzodioxol-5-
ylmethyl)-1-piperazinyl]pyrimidine (piribedil), 4-[2-
10 (dipropylamino)ethyl]indolin-2-one (ropinirole), N,N-
diethyl-N'-[(8 α)-6-methylergolin-8-yl]urea (terguride)
and (\pm)-N,N-diethyl-N'-[(3R,4aR*,10aS*)-
1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-
propylbenzo[g]quinolin-3-yl]sulphamide (quinagolide)
15 salts thereof and mixtures thereof. More preferably, the
dopamine agonist is apomorphine or a salt, preferably an
acid-addition salt, thereof, especially the hydrochloride
salt.

It is also preferred that the dopamine agonist is
20 present in the composition in an amount from 0.05 to
10mg, preferably 0.05 to 5mg.

The ability of dopamine receptor agonists to cause
penile erections in rodents has been reported in a review
by Lal (Prog. Neuro-Psychopharmacol. & Biol. Psychiat.,
25 1988, vol 12, pp. 117-164). It has been said that dose,
and presumably plasma concentration, is critical with low
doses of apomorphine or bromocriptine more effective than
higher doses. It has been postulated that the
physiological response is mediated through activation of
30 central D2 receptors, since it has been shown that
domperidone, a peripheral dopamine antagonist, does not
interfere with this response. It is thus believed that
plasma levels of apomorphine which induce dopamine
receptor stimulation in Parkinsonian patients should also
35 be effective in the treatment of male erectile
dysfunction. However, the adverse side-effects, seen
with apomorphine, of nausea, hypotension and sedation
should be minimised by the use of as low a dose as
possible.

Heaton et al, (1995), Urology, 45 : 200-206 reports patients with MED were given apomorphine liquid sub-lingually (doses of 10mg and 20mg), a sub-lingual tablet (5mg) or a slow-dissolving sub-lingual tablet (3mg and 4mg). Plasma levels were not recorded, but all doses and dosage forms were active, although side effects were a problem in some groups.

Van Laar et al, 1996, Movement Disorders, 11: 634-638 reported peak plasma levels after administration of sub-lingual apomorphine tablets (10mg). The peak plasma levels (ng/ml) were 7.0 ± 0.8 in one experiment and 7.4 ± 1.0 in another. In a third experiment, the sub-lingual tablets were acidified with ascorbic acid - the plasma level reduced slightly to 4.3 ± 1.5 .

Since efficacy in the Heaton et al paper was seen with doses as low as 3mg, the peak plasma level to achieve this (based on dose-corrected data from the van Laar paper) would be around 1.3 to 2.2ng/ml.

A study on the therapeutic window of apomorphine in 3 groups of Parkinsonian patients, by the use of stepwise administration of apomorphine by intravenous infusion, demonstrated that it is possible to separate the onset of pharmacological activity and side-effects. Clinical efficacy, in the treatment of symptoms of Parkinson's disease, was seen at mean serum apomorphine levels above 3.8-5.0ng/ml whilst adverse effects were seen at mean serum apomorphine levels above 12.2-18.5ng/ml.

These reports would suggest that treatment of MED with apomorphine should generally aim for plasma levels of at least 1 to 5 ng/ml and should not be allowed to exceed 10ng/ml.

The precise quantity of active ingredient will depend on the dopamine agonist chosen. Typical dose ranges for the dopamine agonists mentioned above are as follows:-

Apomorphine	1-20mg, preferably 1-10mg
N-propylnoraporphine	1-20mg, preferably 1-10mg
Bromocriptine	0.5-10mg, preferably 0.5-5mg
Cabergoline	0.05-2mg, preferably 0.05-0.5mg

	Lisuride	0.05-2mg, preferably 0.05-0.4mg
	Metergoline	4-20mg, preferably 4-8mg
	Naxagolide	0.1-10mg, preferably 0.1-5mg
	Pergolide	0.05-1mg, preferably 0.05-0.5mg
5	Piribedil	1-20mg, preferably 1-10mg
	Ropinirole	0.25-20mg, preferably 0.25-5mg
	Terguride	1-10mg, preferably 1-5mg
	Quinagolide	0.1-5mg, preferably 0.1-1mg

10 Dopamine agonists may produce side effects such as
nausea and vomiting. The composition used in the
invention may be administered in conjunction with an
anti-emetic. The anti-emetic may be conveniently
administered in the same composition as the dopamine
15 agonist.

 Alternatively, the anti-emetic may be administered
separately from the dopamine agonist by any of the usual
oral or parenteral routes of administration, for
instance, by tablets, capsules, suspensions,
20 suppositories, infusions, injections, etc., at a suitable
time which may be before, after or simultaneously with
administration of the dopamine agonist. It is
particularly preferred that the anti-emetic is formulated
in a fast-dispersing dosage form of the type described
25 above as it is envisaged that such a fast-dispersing
dosage form of the anti-emetic would have many of the
advantages associated with such formulations, such as
increased bioavailability, dose reduction, ease of
administration etc. as described above, although the
30 precise advantages observed will depend on the nature of
the anti-emetic chosen.

 It is preferred that the anti-emetic is present in
the composition in an amount of from 1 to 60mg. However,
the precise quantity of anti-emetic to be administered to
35 the patient will depend on the anti-emetic that is
selected. Suitable anti-emetics include anti-histamines,
such as trimethobenzamide; peripheral dopamine
antagonists, such as 5-chloro-1-[1-[3-(2,3-dihydro-
2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-

5 dihydro-2H-benzimidazol-2-one (domperidone) and salts thereof, and serotonin (5-HT₃) receptor antagonists, such as endo-1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H-indazole-3-carboxamide (granisetron), 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one (ondansetron) and 1 α H,5 α H-tropan-3 α -yl indole-3-carboxylate (tropisetron) and salts thereof. Of these, domperidone is especially preferred.

10 Typical dose ranges for the anti-emetics mentioned above are as follows:-

Domperidone	20-120mg, preferably 30-60mg
Granisetron	1-10mg, preferably 1-3mg
Ondansetron	4-32mg, preferably 4-8mg
Tropisetron	1-10mg, preferably 1-5mg
15 N-[p[2-(dimethylamino)-ethoxy]benzyl]-3,4,5,trimethoxybenzamide	750-1000mg

20 Apomorphine is an opium alkaloid. Thus, as mentioned above, when apomorphine or another opium alkaloid or synthetic derivative is selected as the dopamine agonist, further side-effects, such as sedation, respiratory depression, hypotension, bradycardia, sweating and yawning may be produced. However, it has been found that all these side-effects can be treated by 25 administration of an opioid antagonist in conjunction with the opioid dopamine agonist. The opioid antagonist may be conveniently administered in the same composition as the dopamine agonist. Thus, such a composition may also include an anti-emetic in addition to the dopamine agonist and opioid antagonist although this is not 30 essential since the opioid antagonist also counteracts some of the emetic effects of the dopamine agonist. Alternatively, the opioid antagonist may be administered separately from the dopamine agonist by any of the usual 35 oral or parenteral routes of administration at a suitable time which may be before, after or simultaneously with administration of the dopamine agonist. It is

particularly preferred that the opioid antagonist is formulated in a fast-dispersing dosage form of the type described above as it is envisaged that such a fast-dispersing dosage form of the opioid antagonist would exhibit many of the advantages associated with such formulations, such as increased bioavailability, dose reduction, ease of administration etc. as described above, although the precise advantages observed will depend on the nature of the opioid antagonist chosen.

It is preferred that the opioid antagonist is present in the composition in an amount of from 0.5 to 100mg, more preferably 0.5 to 50mg. However, the precise quantity of opioid antagonist to be administered to the patient will depend on the opioid antagonist that is chosen. Suitable opioid antagonists include 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one (naloxone) and 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one (naltrexone) and salts, particularly acid-addition salts and, especially, the hydrochloride, thereof. A typical dose range for naloxone is 0.25-10mg, and for naltrexone is 10-100mg.

Alteration in endocrine function represents about one third of the total organic causes of male erectile dysfunction as reported in Aversa A et al, 1995, Mol Androl 7, 3-4. The administration of testosterone in the fast-dispersing dosage form assists in ameliorating this condition. A typical dosage range for oral administration of testosterone is 10 to 100mg, preferably 10 to 50mg. The composition may contain testosterone alone or in combination with a dopamine agonist.

The invention is further illustrated by the following Examples.

Example 1Preparation of a fast-dispersing dosage form of apomorphine5 (a) Preparation of apomorphine hydrochloride 2.0% dispersion

10 Gelatin (792g) and mannitol (594g) were dispersed in a portion of purified water (16kg) by mixing thoroughly in the bowl of a vacuum mixer. The mix was then heated to 40°C ± 2°C and homogenised for ten minutes. The mix was cooled down to room temperature (20-24°C). When cooled the apomorphine hydrochloride (360g) was added. The mix was homogenised to ensure dissolution of the drug. Citric acid (166.32g) was added gradually with stirring, to 15 adjust the solution pH to 3.0. The remaining water (87.68g) was added to the mixer and the bulk mix homogenised to ensure dissolution was complete.

(b) Preparation of apomorphine hydrochloride 10mg units
500mg of the apomorphine hydrochloride 2.0% dispersion 20 formed in (a) above was dosed into each one of a series of pre-formed blister pockets having a pocket diameter of 16mm. The blister laminate comprised 200µm PVC coated with 40g per square metre PVdC. The product was frozen immediately in a liquid nitrogen freeze tunnel. The 25 frozen product was then stored below -20°C for a minimum of 12 hours prior to freeze-drying in a freeze drier using a drying temperature of +10°C and a chamber pressure of 0.5mbar. The freeze dried units were then inspected for the presence of critical defects and the 30 remainder of the batch sealed with lidding foil consisting of a paper/foil laminate (20µm aluminium). Each blister was then coded with a batch number and overwrapped in a preformed sachet by placing the blister in the sachet and sealing the open end of the sachet 35 completely. Each sachet was then labelled with the product name, batch number, date of manufacture and suppliers name.

Each dosage unit had the following composition:

Ingredient	Parts by Weight	% by weight of composition
Purified water USP/EP*	446.880	89.4
Apomorphine HCl BP/EP	10.000	2.0
Gelatin EP/USNF	22.000	4.4
Mannitol EP/USP	16.500	0.9
Citric Acid EP/USP	4.620	0.9
Total (pH = 3)	500.000	100.0

* Signifies removed during the lyophilisation process.

Example 2

The following formulation was prepared using the process described in Example 1.

Ingredient	Parts by Weight	% by weight of composition
Purified water EP/USP*	433.000	86.60
Apomorphine HCl BP/EP	10.000	2.0
Gelatin EP/USNF	25.000	5.0
Mannitol EP/USP	20.000	4.0
Glycine USP	10.000	2.0
Citric Acid EP/USP	2.000	0.40
Total (pH = 4)	500.000	100.00

* signifies removed during lyophilisation process.

Example 3

Comparative pharmacokinetic study

The objective of this study was to compare the bioavailability of different fast dispersing formulations of apomorphine hydrochloride, prepared by the method of Example 1, following administration to six healthy volunteers.

Due to the emetic properties of apomorphine, subjects were pre-treated with the anti-emetic domperidone. Following two days of domperidone pre-

treatment, subjects were randomised to receive the following apomorphine treatments:

10mg Apomorphine HCl (one unit of Example 1)

10mg Apomorphine HCl (one unit of Example 2)

5 Blood samples for pharmacokinetic analysis were taken pre-dose and at intervals for six hours after each dose of apomorphine. The results are reported in Figure 1 of the accompanying drawings. It will be seen that apomorphine is rapidly absorbed from both formulations of
10 the fast-dispersing dosage form, reaching a maximum concentration in plasma after about 30 minutes.

The following examples further exemplify formulations which can be prepared using the process described in Example 1:

15

Example 4

Ingredient	Parts by Weight	% by weight of composition
Purified Water EP/USP*	438.500	87.70
Apomorphine HCl BP/EP	10.000	2.00
Gelatin EP/USNF	25.000	5.00
Mannitol EP/USP	20.000	4.00
Citric Acid EP/USP	1.500	0.30
Aspartame EP/USNF	2.500	0.50
Peppermint Flavour	2.500	0.50
Total	500.000	100.00

25

* signifies removed during lyophilisation process.

Example 5

	Ingredient	Parts by Weight	% by weight of composition
	Purified Water EP/USP*	215.000	86.00
5	Apomorphine HCl BP/EP	10.000	4.00
	Gelatin EP/USNF	11.500	4.60
	Mannitol EP/USP	10.000	4.00
	Citric Acid EP/USP	1.500	0.60
	Aspartame EP/USNF	2.000	0.80
10	Total	250.000	100.00

* signifies removed during lyophilisation process.

15

Example 6

	Ingredient	Parts by Weight	% by weight of composition
	Purified Water EP/USP*	441.000	88.20
	Apomorphine HCl BP/EP	10.000	2.00
20	Gelatin EP/USNF	25.000	5.00
	Mannitol EP/USP	20.000	4.60
	Citric Acid EP/USP	1.500	0.30
	Aspartame EP/USNF	2.500	0.50
25	Total	500.000	100.00

* signifies removed during lyophilisation process.

Example 7

	Ingredient	Parts by Weight	% by weight of composition
5	Purified Water EP/USP*	425.000	85.00
	Apomorphine HCl BP/EP	10.000	2.00
	Domperidone	20.000	4.00
	Gelatin EP/USNF	20.000	4.00
	Mannitol EP/USP	15.000	3.00
10	Glycine USP	5.000	1.00
	Aspartame EP/USNF	2.500	0.50
	Peppermint Flavour	2.500	0.50
	Total	500.000	100.00

15 * signifies removed during lyophilisation process.

Example 8

	Ingredient	Parts by Weight	% by weight of composition
20	Purified Water EP/USP*	138.2500	92.1667
	Lisuride Maleate	0.2000	0.1333
	Gelatin EP/USNF	6.0000	4.0000
	Mannitol EP/USNF	4.5000	3.0000
25	Aspartame EP/USNF	0.3000	0.2000
	Cherry Flavour	0.7500	0.5000
	Total	150.000	100.0000

30 * signifies removed during lyophilisation process.

Example 9

	Ingredient	Parts by Weight	% by weight of composition
5	Purified Water EP/USP*	138.9500	92.6333
	Pergolide Mesylate	0.2500	0.1667
	Gelatin EP/USNF	6.0000	4.0000
	Mannitol EP/USP	4.5000	3.0000
	Aspartame EP/USNF	0.3000	0.2000
10	Total	150.0000	100.0000

* signifies removed during lyophilisation process.

15

Example 10

	Ingredient	Parts by Weight	% by weight of composition
	Purified Water EP/USP*	226.250	90.50
	Bromocriptine Mesylate	2.500	1.00
20	Gelatin EP/USNF	10.000	4.00
	Mannitol EP/USP	7.500	3.00
	Aspartame EP/USNF	1.250	0.50
	Cherry Flavour	1.250	0.50
	Peppermint Flavour	1.250	0.50
25	Total	250.000	100.00

* signifies removed during lyophilisation process.

Example 11

	Ingredient	Parts by Weight	% by weight of composition
5	Purified Water EP/USP*	137.750	91.8333
	Ropinirole	1.000	0.6667
	Gelatin EP/USNF	6.000	4.0000
	Mannitol EP/USP	4.500	3.0000
	Aspartame EP/USNF	0.750	0.5000
10	Total	150.000	100.0000

* signifies removed during lyophilisation process.

15

Example 12

	Ingredient	Parts by Weight	% by weight of composition
	Purified Water EP/USP*	431.500	86.30
	Apomorphine HCl BP/EP	10.000	2.00
20	Naloxone HCl BP/EP	10.000	2.00
	Gelatin EP/USNF	20.500	4.10
	Mannitol EP/USP	15.000	3.00
	Citric Acid EP/USP	1.500	0.30
	Aspartame EP/USNF	3.000	0.60
25	Grapefruit Flavour	1.000	0.20
	Glycine USP	7.500	1.50
	Total	500.000	100.00

* signifies removed during lyophilisation process.

30

Example 13

	Ingredient	Parts by Weight	% by weight of composition
5	Purified Water EP/USP*	413.000	82.60
	Apomorphine HCl BP/EP	10.000	2.00
	Naltrexone HCl	25.000	5.00
	Gelatin EP/USNF	22.500	4.50
	Mannitol EP/USP	15.000	3.00
10	Citric Acid EP/USP	2.500	0.50
	Aspartame EP/USNF	5.000	1.00
	Raspberry Flavour	2.000	0.40
	Glycine USP	5.000	1.00
	Total	500.000	100.00

15

* signifies removed during lyophilisation process.

Example 14

	Ingredient	Parts by Weight	% by weight of composition
20	Purified Water EP/USP*	397.250	79.45
	Apomorphine HCl BP/EP	20.000	4.00
	Naloxone HCl BP/EP	10.000	2.00
	Domperidone	20.000	4.00
25	Gelatin EP/USNF	22.500	4.50
	Mannitol EP/USP	17.500	3.50
	Citric Acid EP/USP	1.500	0.30
	Lemon Lime Flavour	2.500	4.50
	Glycine USP	5.000	1.00
30	Aspartame EP/USNF	3.750	0.75
	Total	500.000	100.00

* signifies removed during lyophilisation process.

35

Example 15

	Ingredient	Parts by Weight	% by weight of composition
5	Purified Water EP/USP*	219.008	87.60
	Apomorphine HCl BP/EP	5.000	2.00
	Granisetron HCl	1.117	0.45
	Gelatin EP/USNF	10.625	4.25
	Mannitol EP/USP	7.500	3.00
10	Citric Acid EP/USP	1.500	0.60
	Mint Flavour	1.500	0.60
	Glycine USP	1.250	0.50
	Aspartame EP/USNF	2.500	1.00
	Total	250.000	100.00

15

* signifies removed during lyophilisation process.

Example 16

	Ingredient	Parts by Weight	% by weight of composition
20	Purified Water EP/USP*	416.0	83.2
	Gelatin	18.0	3.6
	Mannitol	13.5	2.7
	Testosterone undecanoate	50.0	10.0
25	Aspartame	2.5	0.5
		500.00	100.0


* signifies removed during lyophilisation process.

CLAIMS

1. The use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, testosterone and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male erectile dysfunction.
2. The use to claim 1 in which the composition is in the form of a solid fast-dispersing dosage form comprising a network of the active ingredient and a water-soluble or water-dispersible carrier which is inert towards the active ingredient, the network having been obtained by subliming solvent from a composition in the solid state, that composition comprising the active ingredient and a solution of the carrier in a solvent.
3. The use according to claim 1 or claim 2 in which the composition disintegrates within 1 to 60 seconds of being placed in the oral cavity.
4. The use according to any one of the preceding claims in which the dopamine agonist is apomorphine or a salt thereof.
5. The use according to any one of the preceding claims in which the active ingredient is present in an amount of from 0.05 to 50 mg.
6. The use according to any one of the preceding claims which further includes an anti-emetic.

7. The use according to claim 6 in which the anti-emetic is present in an amount of from 1 to 120mg.
- 5 8. The use according to any one of claims 4 to 7 which further includes an opioid antagonist.
9. The use according to claim 8 in which the opioid antagonist is present in an amount of from 0.5 to 100mg.
- 10 10. The use as claimed in any preceding claim in which the active ingredient comprises testosterone.
11. The use as claimed in claim 10 in which the
15 testosterone is present in an amount of 10 to 100mg.
12. A method of treating male erectile dysfunction which comprises administering to the oral cavity of a patient a dopamine agonist and/or testosterone in a fast-dispersing dosage form designed to release active
20 ingredients rapidly in the oral cavity.
13. A method as claimed in claim 12 which comprises administering a pharmaceutical composition as defined in
25 any one of claims 2 to 10.

Figure 1



INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00143

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K31/485 A61K31/565 A61K9/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 28930 A (PENTECH) 2 November 1995 cited in the application see the whole document ---	1,3-5, 12,13
X	WO 96 41619 A (PENTECH) 27 December 1996 see the whole document ---	1,3-5, 12,13
Y	US 5 135 752 A (W.C.SNIPES) 4 August 1992 see claims ---	1-13
Y	US 4 877 774 A (J.PITHA ET AL.) 31 October 1989 see the whole document ---	1-13
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 22 April 1998		Date of mailing of the international search report 08/05/1998
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Scarponi, U

INTERNATIONAL SEARCH REPORT

Inter. 1al Application No

PCT/GB 98/00143

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3 928 566 A (A.R.BRIGGS) 23 December 1975 see claims 1-4 see example VIII ---	1-13
Y	GB 1 548 022 A (JOHN WYETH) 4 July 1979 cited in the application see the whole document ---	1-13
Y	WO 95 20377 A (UNIVERSITY OF OKLAHOMA) 3 August 1995 see the whole document ---	1-13
Y	DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US ACCESSION NR. 95159287, XP002063017 see abstract & J. P. HEATON ET AL.: "RECOVERY OF ERECTILE FUNCTION BY THE ORAL ADMINISTRATION OF APOMORPHINE" UROLOGY, vol. 45, no. 2, 1995, pages 200-206, ---	1-13
Y,P	WO 97 06786 A (R.P.SCHERER LTD.,UK) 27 February 1997 cited in the application see the whole document -----	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00143

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9528930 A	02-11-95	AU 2295895 A	16-11-95
		CA 2188385 A	02-11-95
		EP 0758895 A	26-02-97
		JP 9512273 T	09-12-97
WO 9641619 A	27-12-96	US 5624677 A	29-04-97
		AU 6174996 A	09-01-97
		EP 0833619 A	08-04-98
US 5135752 A	04-08-92	AT 119044 T	15-03-95
		AU 625683 B	16-07-92
		AU 4422889 A	01-05-90
		CA 2000697 A	14-04-90
		DE 68921463 D	06-04-95
		DE 68921463 T	29-06-95
		EP 0390911 A	10-10-90
		JP 3501737 T	18-04-91
		WO 9003776 A	19-04-90
		US 5004601 A	02-04-91
		US 5139790 A	18-08-92
		US 5244668 A	14-09-93
US 4877774 A	31-10-89	NONE	
US 3928566 A	23-12-75	US 3932943 A	20-01-76
		CH 573767 A	31-03-76
		DE 2140747 A	17-02-72
		FR 2104349 A	14-04-72
		GB 1316522 A	09-05-73
		NL 7111106 A	16-02-72
		SE 395221 B	08-08-77
		US 3721725 A	20-03-73
		CA 980249 A	23-12-75
		CH 574590 A	15-04-76
		DE 2243014 A	08-03-73
		FR 2154452 A	11-05-73
		GB 1395651 A	29-05-75
		NL 7211923 A,B,	06-03-73
		SE 425461 B	04-10-82

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00143

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1548022 A	04-07-79	AU 513845 B	08-01-81
		AU 2882577 A	22-03-79
		BE 859291 A	30-03-78
		CA 1083042 A	05-08-80
		CH 633717 A	31-12-82
		CY 1129 A	19-02-82
		DE 2744493 A	13-04-78
		FR 2366835 A	05-05-78
		HK 58081 A	04-12-81
		JP 1446344 C	30-06-88
		JP 53044619 A	21-04-78
		JP 62050445 B	24-10-87
		JP 1509556 C	26-07-89
		JP 61118314 A	05-06-86
		JP 63052008 B	17-10-88
		KE 3171 A	18-12-81
		LU 78259 A	09-06-78
		NL 7710876 A,B,	10-04-78
		US 4371516 A	01-02-83
		ZA 7705465 A	25-04-79
WO 9520377 A	03-08-95	US 5595761 A	21-01-97
		AU 680345 B	24-07-97
		AU 1688595 A	15-08-95
		BG 100749 A	28-02-97
		CA 2181990 A	03-08-95
		CN 1139877 A	08-01-97
		CZ 9602068 A	11-12-96
		EP 0743850 A	27-11-96
		FI 962989 A	26-07-96
		HU 74514 A	28-01-97
		JP 9511489 T	18-11-97
		NO 963140 A	25-09-96
		NZ 279674 A	24-02-97
		PL 315685 A	25-11-96
		SK 91096 A	04-06-97
		US 5587180 A	24-12-96
		ZA 9500677 A	08-05-96
		US 5635210 A	03-06-97

Information on patent family members

Internal Application No

PCT/GB 98/00143

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9706786 A	27-02-97	AU 6750996 A	12-03-97